Automatic Sound Management 3.0 in a Single-unit Audio Processor — RND3  

Cochlear Implants Clinical Trial

Official title: Automatic Sound Management 3.0 in a Single-unit Audio Processor

Status Completed

Clinical Trial Summary

Cochlear implants are routine treatment for people with severe hearing loss. This study tests the RONDO 3, MED-EL's newest single-unit audio processor which comes with new features (Beamformer, Wind-Noise reduction, Ambient noise reduction, Transient noise reduction, Adaptive intelligence).

Clinical Trial Description

MED-EL Cochlear Implants (CI) provide auditory sensations via electrical stimulation of the auditory pathways for severely to profoundly hearing-impaired individuals who obtain little or no benefit from acoustic amplification in the best aided condition. Front-end processing of acoustic signals picked up by the audio processor is routinely applied to provide optimal hearing performance under varying listening conditions. Automatic Sound Management (ASM) was introduced by MED-EL with the TEMPO+ audio processor and provided advanced compression and automatic gain management. With the SONNET audio processor, MED-EL introduced ASM 2.0, which added wind noise reduction and microphone directionality to the front-end processing. With the SONNET 2 audio processor, ASM 3.0 was implemented and the features ambient noise reduction, transient noise reduction and an adaptive intelligence (AI) were added. The RONDO 3 implements now ASM 3.0.

This study investigates the impact of ASM 3.0 as implemented in the RONDO 3 on CI users' speech performance and their subjective quality of hearing. ;

Related Conditions & MeSH terms

• Cochlear Implants

• NCT number: NCT04918654
• Study type: Observational
• Source: MED-EL Elektromedizinische Geräte GesmbH
• Status: Completed
• Start date: June 25, 2021
• Completion date: December 11, 2023